WCN26-4078 EFFECT OF ONCE-WEEKLY SEMAGLUTIDE 1.0 MG ON KIDNEY OUTCOMES BY BASELINE CHARACTERISTICS: EXPLORATORY DATA FROM THE FLOW TRIAL

Read full text Summarise with VIRAT
Authors: Srikanth Bellary, Richard E. Pratley, Katherine R. Tuttle, Peter R Rossing, Kenneth W. Mahaffey, Prachi Priyadarshini, Christine Sofie Fuchs Jacobsen, Poornima Kn, Johannes F.E. Mann
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background and aims: In the FLOW trial (NCT03819153), semaglutide reduced the risk of major kidney and cardiovascular (CV) events and all-cause death. This analysis explored the effect of semaglutide on key kidney outcomes by baseline characteristics.

Fields of Study & Subjects

Chronic Kidney Disease and Diabetes Diabetes Treatment and Management Heart Failure Treatment and Management

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104616–104616
Publication date
25 March 2026
Language
EN